Last reviewed · How we verify

MRTX849 — Competitive Intelligence Brief

MRTX849 (MRTX849) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: KRAS G12C inhibitor. Area: Oncology.

phase 3 KRAS G12C inhibitor KRAS G12C Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MRTX849 (MRTX849) — Mirati Therapeutics Inc.. MRTX849 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MRTX849 TARGET MRTX849 Mirati Therapeutics Inc. phase 3 KRAS G12C inhibitor KRAS G12C
AMG 510 AMG 510 Criterium, Inc. phase 3 KRAS G12C inhibitor KRAS G12C
RMC-6236 RMC-6236 Revolution Medicines, Inc. phase 3 KRAS G12C inhibitor KRAS G12C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (KRAS G12C inhibitor class)

  1. Criterium, Inc. · 1 drug in this class
  2. Dark Canyon Laboratories, LLC · 1 drug in this class
  3. Mirati Therapeutics Inc. · 1 drug in this class
  4. Revolution Medicines, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MRTX849 — Competitive Intelligence Brief. https://druglandscape.com/ci/mrtx849. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: